Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...

Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early ...

Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

With the American Society of Clinical Oncology (ASCO) annual meeting in full swing at Chicago’s McCormick Place this past ...

NHS frameworks, such as Patient and Public Involvement, have demonstrated the value of integrating patient perspectives into ...

With 90 percent of clinical trials failing to reach completion, there is an urgent need for innovative techniques that blend scientific rigor with patient-centered strategies. This discussion will ...

Muse has reached a major milestone with the recent launch of Muse S Athena, the first wearable to integrate clinical-grade ...

Shares in MaaT Pharma (Euronext: MAAT), a French microbiome company in oncology, closed 25% higher Tuesday. The company ...

The healthcare tech firm's stock fell as much as 4.68 per cent during the day to ₹590 per share, the biggest intraday loss ...

Momentum continues to build for Lamassu Biotech's pioneering treatment protocol for acute pancreatitis in canines. The private, clinical stage biopharmaceutical company has received a $2.7 million ...

Carlyle affiliate CA Dawn Investments has offered to sell over 2.4 crore shares at a floor price of Rs 580 per share, ...